Long-term Efficacy and Safety of HMS5552 in T2DM Subjects

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 463 participants.

Also called NCT03173391

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 463 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03173391
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03173391. Randomized; quadruple masking; primary purpose treatment. Start 2017-07-18 (actual); primary completion 2020-11-30 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Long-term Efficacy and Safety of HMS5552 in T2DM Subjects
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
HMS5552
Intervention (Drug)
Placebo
Lead sponsor
Hua Medicine Limited (class: industry)
Collaborator
Tigermed Consulting Co., Ltd (class: industry)

Record details

Record id
cardio:ct-nct03173391
Content hash
aae864f0f7a0b19f1bf757f0dc4e7a800fb95f4b2ce8c2ce9234e03bf208a165